Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pirarubicin (THP-adriamycin)].

S Tsukagoshi1

  • 1Cancer Chemotherapy Center, Cancer Institute, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 1, 1988
PubMed
Summary

Pirarubicin (THP-adriamycin) is a novel anthracycline antibiotic effective against various cancers, including drug-resistant types. It shows a broad clinical spectrum with reduced toxicity compared to other anthracyclines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VALIDATION OF MONTE CARLO DOSE CALCULATION FOR PAEDIATRIC CT EXAMINATIONS USING TUBE CURRENT MODULATION BASED ON IN-PHANTOM DOSIMETRY.

Radiation protection dosimetry·2018
Same author

Buruli ulcer in a nine-month-old boy.

Annals of the Royal College of Surgeons of England·2012
Same author

[Comparison of management of advanced cancer in various organs].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].

Hinyokika kiyo. Acta urologica Japonica·2001

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Context:

  • Anthracycline antibiotics are crucial in cancer chemotherapy.
  • Doxorubicin resistance presents a significant clinical challenge.
  • Development of less toxic and broadly effective anticancer agents is a priority.

Purpose:

  • To introduce Pirarubicin (THP-adriamycin), a 4'-O-substituted anthracycline.
  • To evaluate its preclinical and clinical efficacy and toxicity profile.
  • To assess its potential as a therapeutic agent for human solid tumors.

Summary:

  • Pirarubicin demonstrated comparable antitumor efficacy to doxorubicin in preclinical studies.
  • It exhibited activity against doxorubicin-resistant murine tumor cell lines.
  • The drug inhibits DNA polymerase alpha, leading to suppressed DNA synthesis.
  • Clinical studies revealed responses in head and neck, breast, urogenital, ovarian, and uterine cancers, acute leukemia, and malignant lymphoma.
  • Pirarubicin exhibited a favorable side effect profile, with mild cardiac, alopecia, and digestive toxicities.

Impact:

  • Pirarubicin offers a potential alternative for patients with anthracycline-resistant cancers.
  • Its reduced toxicity profile may improve patient tolerability and quality of life.
  • The drug's broad antitumor spectrum suggests wide applicability in clinical oncology.

Related Experiment Videos